<div id="readability-page-1"><p>Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) shares gapped down prior to trading on Friday after Oppenheimer downgraded the stock from an outperform rating to a market perform rating. The stock had previously closed at $14.68, but opened at $14.13. Dyne Therapeutics shares last traded at $14.13, with a volume of 210,969 shares changing hands.</p><p>Several other equities research analysts have also recently weighed in on the company. JPMorgan Chase &amp; Co. decreased their target price on Dyne Therapeutics from $10.00 to $9.00 and set a &#34;neutral&#34; rating for the company in a research note on Tuesday, July 15th. Jones Trading started coverage on Dyne Therapeutics in a research note on Thursday, June 26th. They set a &#34;buy&#34; rating and a $30.00 target price for the company. Sanford C. Bernstein started coverage on Dyne Therapeutics in a research note on Tuesday, June 24th. They set a &#34;market perform&#34; rating and a $13.00 target price for the company. Chardan Capital cut their price target on Dyne Therapeutics from $50.00 to $38.00 and set a &#34;buy&#34; rating on the stock in a research report on Tuesday, July 29th. Finally, Guggenheim  reaffirmed a &#34;buy&#34; rating and set a $50.00 price target on shares of Dyne Therapeutics in a research report on Wednesday, June 18th. Three research analysts have rated the stock with a Strong Buy rating, ten have assigned  a Buy rating, three have given a Hold rating and one  has given a Sell rating to the stock. Based on data from MarketBeat, the company  has an average rating of &#34;Moderate Buy&#34; and an average target price of $34.07.</p><div><p><span></span><span>Get <strong>Dyne Therapeutics</strong> alerts:</span></p></div><p><b>Get Our Latest Stock Report on DYN</b></p><h2>Insider Activity</h2><p>In related news, CEO John Cox bought 100,000 shares of the company's stock in a transaction dated Monday, July 14th. The shares were acquired at an average price of $9.11 per share, with a total value of $911,000.00. Following the completion of the acquisition, the chief executive officer owned 242,179 shares in the company, valued at approximately $2,206,250.69. This trade represents a 70.33% increase in their position. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is accessible through this hyperlink. Insiders own  14.14% of the company's stock. </p><h2>Institutional Inflows and Outflows</h2><p>Institutional investors have recently modified their holdings of the stock. GAMMA Investing LLC increased its holdings in shares of  Dyne Therapeutics by 837.5% in the first quarter. GAMMA Investing LLC now owns 2,625 shares of the company's stock valued at $251,000 after purchasing an additional 2,345 shares during the period.  CWM LLC boosted its stake in shares of  Dyne Therapeutics by 168.1% in the second quarter. CWM LLC now owns 3,030 shares of the company's stock valued at $29,000 after buying an additional 1,900 shares in the last quarter.  Caitong International Asset Management Co. Ltd boosted its stake in shares of  Dyne Therapeutics by 378.6% in the first quarter. Caitong International Asset Management Co. Ltd now owns 3,092 shares of the company's stock valued at $32,000 after buying an additional 2,446 shares in the last quarter.  Quarry LP purchased a new stake in shares of  Dyne Therapeutics in the first quarter valued at approximately $47,000.  Finally, Ameritas Investment Partners Inc. boosted its stake in shares of  Dyne Therapeutics by 11.1% in the second quarter. Ameritas Investment Partners Inc. now owns 9,582 shares of the company's stock valued at $91,000 after buying an additional 955 shares in the last quarter. Institutional investors and hedge funds own  96.68% of the company's stock. </p><h2>Dyne Therapeutics Stock Performance</h2><p>The company has a debt-to-equity ratio of 0.17, a current ratio of 16.83 and a quick ratio of 16.83. The stock has a market capitalization of $2.00 billion, a PE ratio of -3.66 and a beta of 1.09. The stock has a 50 day moving average of $12.76 and a two-hundred day moving average of $11.25. </p><p>Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last posted its quarterly earnings results on Monday, July 28th. The company reported ($0.97) earnings per share for the quarter, beating analysts' consensus estimates of ($0.99) by $0.02.  Research analysts expect that  Dyne Therapeutics, Inc. will post -3.44 EPS for the current fiscal year. </p><h2>About Dyne Therapeutics</h2> (Get Free Report)<p>Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.</p><h2>Read More</h2><ul><li>Five stocks we like better than Dyne Therapeutics</li><li>Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?</li><li>How Gamers Are Powering Microsoft’s Next Wave of Growth</li><li>Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?</li><li>Big Gains Alert: These 3 Tech Stocks Are Surging This Month</li><li>High Flyers: 3 Natural Gas Stocks for March 2022</li><li>Coca-Cola Stock Dips—Is CELH the Growth Your Portfolio Needs?</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Dyne Therapeutics Right Now?</h2><p>Before you consider Dyne Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dyne Therapeutics wasn't on the list.</p><p>While Dyne Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Dyne Therapeutics (NASDAQ:DYN) shares gapped down after Oppenheimer downgraded the stock from outperform to market perform, opening at $14.13 from a previous close of $14.68. Analysts have mixed ratings, with a target price range from $9.00 to $50.00. CEO John Cox purchased 100,000 shares at $9.11 each, increasing his stake significantly. Institutional investors hold 96.68% of the stock. The company reported a quarterly EPS of ($0.97), slightly beating estimates, and is focused on therapeutics for muscle diseases.</p>

Dyne Therapeutics (NASDAQ:DYN) Shares Gap Down After Analyst Downgrade